+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Urinary Incontinence (Genitourinary Disorders) - Drugs in Development, 2021

  • ID: 5331218
  • Drug Pipelines
  • March 2021
  • Region: Global
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Cook MyoSite Inc
  • Exopharm Ltd
  • Johnson & Johnson
  • Outpost Medicine Ltd
  • Profem GmbH
  • RION Health Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Drugs in Development, 2021, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 9 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Cook MyoSite Inc
  • Exopharm Ltd
  • Johnson & Johnson
  • Outpost Medicine Ltd
  • Profem GmbH
  • RION Health Inc

Introduction
  • Report Coverage

Urinary Incontinence - Overview
Urinary Incontinence - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Urinary Incontinence - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Urinary Incontinence - Companies Involved in Therapeutics Development
  • Cook MyoSite Inc
  • Crystec Ltd
  • Exopharm Ltd
  • FemmePharma Global Healthcare Inc
  • Innovacell Biotechnologie AG
  • Ixaltis
  • Johnson & Johnson
  • MUVON Therapeutics AG
  • Ningbo Xijian Pharmaceutical Technology Co Ltd
  • Outpost Medicine Ltd
  • Pfizer Inc
  • Profem GmbH
  • Revance Therapeutics Inc
  • RION Health Inc
  • Saniona AB
  • Sinsin Pharmaceutical Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • Versameb AG

Urinary Incontinence - Drug Profiles
Biologic for Stress Urinary Incontinence - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Cell Therapy for Stress Urinary Incontinence - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Cell Therapy for Urinary Incontinence - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Cell Therapy for Urinary Stress Incontinence - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Cevaris - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

EG-017 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ICES-13 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

iltamiocel - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

litoxetine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Oligonucleotides for Stress Urinary Incontinence - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

onabotulinumtoxinA biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

OP-352 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

oxybutynin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

oxybutynin chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Prof-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

TAS-303 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

tolterodine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

trospium chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Urinary Incontinence - Dormant Projects
  • Urinary Incontinence - Discontinued Products

Urinary Incontinence - Product Development Milestones
  • Featured News & Press Releases
  • Dec 17, 2020: FDA grants RMAT designation for Cook MyoSite’s investigational autologous Muscle Derived Cells for Urinary Sphincter Repair
  • Jan 11, 2018: Sleep quality improves with help of incontinence drug
  • Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence
  • Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
  • Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
  • Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
  • Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency
  • Aug 30, 2011: Innovacell passes a further milestone
  • Feb 22, 2011: Innovacell makes further progress on product development
  • Jun 15, 2010: Innovacell Enrolls First Patient In Phase IIb Study Of Urocell For Treatment Of Urinary Incontinence
  • Oct 31, 2008: Fesoterodine Approved in the U.S
  • Sep 15, 2003: FemmePharma Receives U.S. Ind Approval for its New Therapeutic Option for Female Urinary Incontinence

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Urinary Incontinence, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Urinary Incontinence - Pipeline by Cook MyoSite Inc, 2021
  • Urinary Incontinence - Pipeline by Crystec Ltd, 2021
  • Urinary Incontinence - Pipeline by Exopharm Ltd, 2021
  • Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, 2021
  • Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, 2021
  • Urinary Incontinence - Pipeline by Ixaltis, 2021
  • Urinary Incontinence - Pipeline by Johnson & Johnson, 2021
  • Urinary Incontinence - Pipeline by MUVON Therapeutics AG, 2021
  • Urinary Incontinence - Pipeline by Ningbo Xijian Pharmaceutical Technology Co Ltd, 2021
  • Urinary Incontinence - Pipeline by Outpost Medicine Ltd, 2021
  • Urinary Incontinence - Pipeline by Pfizer Inc, 2021
  • Urinary Incontinence - Pipeline by Profem GmbH, 2021
  • Urinary Incontinence - Pipeline by Revance Therapeutics Inc, 2021
  • Urinary Incontinence - Pipeline by RION Health Inc, 2021
  • Urinary Incontinence - Pipeline by Saniona AB, 2021
  • Urinary Incontinence - Pipeline by Sinsin Pharmaceutical Co Ltd, 2021
  • Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, 2021
  • Urinary Incontinence - Pipeline by Versameb AG, 2021
  • Urinary Incontinence - Dormant Projects, 2021
  • Urinary Incontinence - Dormant Projects, 2021 (Contd..1)
  • Urinary Incontinence - Dormant Projects, 2021 (Contd..2)
  • Urinary Incontinence - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Urinary Incontinence, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Cook MyoSite Inc
  • Crystec Ltd
  • Exopharm Ltd
  • FemmePharma Global Healthcare Inc
  • Innovacell Biotechnologie AG
  • Ixaltis
  • Johnson & Johnson
  • MUVON Therapeutics AG
  • Ningbo Xijian Pharmaceutical Technology Co Ltd
  • Outpost Medicine Ltd
  • Pfizer Inc
  • Profem GmbH
  • Revance Therapeutics Inc
  • RION Health Inc
  • Saniona AB
  • Sinsin Pharmaceutical Co Ltd
  • Taiho Pharmaceutical Co Ltd
  • Versameb AG
Note: Product cover images may vary from those shown